MedTrace Logo

Immune Durability After VSV-EBOV Vaccination

NCT02933931 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2021-05-26

No results posted yet for this study

Summary

This prospective observational cohort study will follow the roughly 100 adults who received the VSV-ZEBOV vaccine in the Geneva phase 1 randomized controlled trial in 2014-2015 in order to determine their long-term (5-year) immune response to vaccination.

Conditions

  • Immune Response
  • Vaccination
  • Durability

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Claire-Anne Siegrist, MD · University of Geneva

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-01-31
Completion
2020-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933931 on ClinicalTrials.gov